Clinical trials: Hematologic
Invasive Fungal Disease, Chronic Disseminated Candidiasis
Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis
The purpose of this study is to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
- Conditions
- Invasive Fungal Disease, Chronic Disseminated Candidiasis, Hematological Malignancies, Hematopoietic Stem Cell Transplantation
- Trial name
- CANHPARI (NCT01916057)
- Testing
- 18F-FDG PET Scan
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NHL, Large Cell Lymphoma
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Background: One type of cancer therapy takes blood cells from a person, changes them in a lab, then gives the cells back to the person.
- Conditions
- NHL, Large Cell Lymphoma, Follicular Lymphoma, ALL
- Trial name
- NCT02315612
- Testing
- CD22-CAR
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
The study is an early, open, single-centered trial. The purpose of this study is to evaluate the safety and persistence of BCMA/CD19 dual-target CAR-T cell immunotherapy in relapsed or refractory MM.
- Trial name
- NCT04182581
- Testing
- BCMA/CD19 Dual-Target CAR-T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Xijing Hospital
Covid19
Hematology and Clinical Picture in Pediatric COVID-19 Infection
This study is to discuss the different clinical presentations, hematological and laboratory abnormalities in pediatric COVID-19 infection.
- Trial name
- NCT04487119
- Where
- Egypt
- Volunteers
- 29 people
- Sponsor
- Benha University
Hematological Malignancies
Safety and Efficacy Evaluation of IM19 Cells
Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies.
- Trial name
- NCT03344705
- Testing
- IM19 CAR-T, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Lymphoma
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia
RATIONALE: Monoclonal antibodies such as yttrium Y 90 ibritumomab tiuxetan and rituximab can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00060294
- Testing
- rituximab, yttrium Y 90 ibritumomab tiuxetan
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
The purpose of this study is to determine the response rate of the combination of bortezomib and melphalan in patients with Acute Myelogenous Leukemia (AML) or high-risk Myelodysplastic Syndromes (MDS).
- Trial name
- NCT00789256
- Testing
- Melphalan, Bortezomib, Melphalan and bortezomib
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Sickle Cell Disease
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
This phase I trial tests the safety and effectiveness of total marrow and lymphoid irradiation (TMLI) and alemtuzumab as a conditioning regimen in patients with sickle cell disease.
- Trial name
- NCT05384756
- Testing
- Alemtuzumab, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003956
- Testing
- fluorouracil, leucovorin calcium, lonafarnib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Oral Clofarabine Study in Patients With Myelodysplastic Syndrome
The goal of this clinical research study is to learn if clofarabine given by mouth on a weekly schedule can help to control MDS. The safety of clofarabine given by mouth will also be studied.
- Trial name
- NCT00299156
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Hip Fracture, Surgical Intervention
Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia
The purpose of this study is to evaluate the safety and efficacy of intravenous iron sucrose in patients with hip fracture and surgical intervention to prevent perioperative anemia.
- Trial name
- NCT01084122
- Testing
- Iron sucrose
- Where
- Spain
- Volunteers
- 360 people
- Sponsor
- Hospital Clinic of Barcelona
Anemia, Aortic Stenosis
Erythropoietin + Iron Therapy for Anemic Patients Undergoing Aortic Valve Replacement
The objective of the study is to evaluate the efficacy of Erythropoietin (EPO) (+ iron) in reducing the rate of red blood cell transfusion requirements in patients with aortic stenosis undergoing transcatheter aortic valve…
- Trial name
- EPICURE (NCT02390102)
- Testing
- Erythropoietin
- Where
- Canada
- Volunteers
- 117 people
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
ALS, Autism Spectrum Disorder
Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products
This is an observational study of medical marijuana manufactured and dispensed by Ilera and given as standard treatment for a variety of approved serious medical conditions as defined by individual state law.
- Conditions
- ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle
- Trial name
- Ilera (NCT03886753)
- Testing
- Registry, PK microsampling of blood
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital of Philadelphia
SARS-CoV-2 Infection, Hematologic Malignancy
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors
The goal of this observational study is to compare the immune function and infection mechanism of patients with hematologic tumors and those people without underlying diseases after infection with SARS-CoV-2.
- Trial name
- NCT05683353
- Testing
- None intervention
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Multiple Myeloma
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Eligible participants with newly diagnosed myeloma who are not considered eligible or refuse bone marrow transplant will be enrolled.
- Trial name
- PrE1005 (NCT07285239)
- Testing
- Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- PrECOG, LLC.
Trauma Injury, Trauma
The Role of Brain-Bone Marrow-Gut Interaction Following Major Trauma
Traumatic injury followed by critical illness provokes pathophysiologic changes in the bone marrow and the gut that contribute to persistent anemia and changes in the microbiome which significantly impact long-term recovery.
- Conditions
- Trauma Injury, Trauma, Critical Illness, Microbiome
- Trial name
- NCT06606119
- Testing
- Data and tissue collection
- Where
- 3 sites in United States
- Volunteers
- 275 people
- Sponsor
- University of Florida
Hematologic Malignancy, Solid Tumor
Voraxaze for Delayed Methotrexate Clearance
Primary Objectives: 1. To evaluate the efficacy of Glucarpidase (Voraxaze) in increasing the rate of methotrexate (MTX) clearance following high dose MTX treatment in patients with a delayed MTX clearance. 2.
- Trial name
- NCT00424645
- Testing
- Voraxaze (Glucarpidase)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
B-cell Chronic Lymphocytic Leukemia
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the…
- Trial name
- NCT00774345
- Testing
- Lenalidomide
- Where
- 241 sites in United States, Australia and 23 more
- Volunteers
- 317 people
- Sponsor
- Celgene
Lymphoma, Multiple Myeloma
Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor
In the European Union (EU), plerixafor is indicated in combination with granulocyte colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells (HSCs) to the peripheral blood (PB) for collection and…
- Trial name
- NCT01362972
- Volunteers
- 7,801 people
- Sponsor
- Genzyme, a Sanofi Company
Pediatric Leukemia, Pediatric Brain Neoplasms
Feasibility of Identifying a Chinese Study Population and Eligible Pediatric Cancer Cases, and Linking the Two Groups to Assess the Role of Periconceptional Folic Acid Supplements in Risk of Pediatric Cancer.
Background: Pregnant women are encouraged to take the vitamin folate. It helps prevent some birth defects. Children of mothers who take it also have less risk of some cancers.
- Conditions
- Pediatric Leukemia, Pediatric Brain Neoplasms, Other Pediatric Cancers
- Trial name
- NCT02160795
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.